Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
General17 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News23 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General22 hours agoAustralia welcomes Gaza peace progress, hostage release
-
General15 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell